Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|AALL15P1||COG||A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement||Pediatric CIRB||Available to Open|
|10246||ETCTN||A Phase 1 Study of MLN4924 (pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome||Adult CIRB - Early Phase Emphasis||Available to Open|
|10066||ETCTN||A Phase 1 / 2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma||Adult CIRB - Early Phase Emphasis||Available to Open|
|ABTC-1801||ABTC||Phase I/II Study of Pamiparib (BGB-290) with Temozolomide in Recurrent Gliomas with IDH1/2 Mutations||Adult CIRB - Early Phase Emphasis||Available to Open|
|A011203||Alliance||A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women with Metastatic; Estrogen Receptor Positive; HER2 Negative Breast Cancer||Adult CIRB - Early Phase Emphasis||Available to Open|
|EAQ152||ECOG-ACRIN||A Randomized Study of Pre-disclosure Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling||Adult CIRB - Early Phase Emphasis||Available to Open|
|9979||ETCTN||Phase 1 and Pharmacology Study of Oral 5-iodo-2-pyrimidinone-2-deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases||Adult CIRB - Early Phase Emphasis||Available to Open|
|PEPN1812||PEP-CTN||A Phase 1 Trial of the CD123 X CD3 DART® Molecule Flotetuzumab (NSC#808294, IND#145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia||Pediatric CIRB||Available to Open|
|ALTE2031||COG||StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors||Pediatric CIRB||Available to Open|
|ANHL04B1||COG||Rare and Cutaneous Non-Hodgkin Lymphoma Registry||Pediatric CIRB||Available to Open|